Women who take GLP-1 medications, such as Ozempic or Mounjaro, are less likely to develop breast cancer, a new study has found.
The findings, presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting, come from an analysis of more than 110,000 women aged between 45 and 80.
